Published Date: 13 Sep 2024
Novel agent nearly halved risk of progression as first-line therapy in phase III trial
Read Full NewsUltragenyx seeks FDA accelerated approval for UX111 gene therapy in Sanfilippo syndrome, citing neurologic benefit and the use of cerebral spinal fluid heparan sulfate data.
Here's some of what is coming soon to NeurologyLive® this week.
AGNOS trial showed that monthly treatment with ofatumumab lowered NfL and GFAP in patients with early RRMS, signaling reduced nerve damage and bolstering first-line treatment potential.
Pediatric neurologist Charuta Joshi, MD, discussed global disparities in epilepsy for children and adolescents amid International Epilepsy Day, highlighting opportunities for education, stigma reduction, and improved care access.
The FDA issued a CRL for gene therapy RGX-121 in Hunter syndrome, citing trial design and biomarker doubts; Regenxbio seeks a meeting with the agency and resubmission.
In this interview, Siegel highlights key points presented in his Maui Derm 2026 talk, 'How To Maximize Your Billing Effectiveness in the Era of Dwindling Reimbursements and ICD-10.'
New Phase 3 Findings Support Ameluz-PDT for Patients with Actinic Keratosis
1.
AI Model as Effective as Radiologists in Detecting Prostate Cancer on MRI
2.
Getting Lung Cancer Screening Staff Involved Improved Tobacco Cessation
3.
When it comes to LBCL relapse in complete remission, ASCT outperforms CAR T-cell therapy.
4.
No Laughing Matter: Nitrous Oxide for Transrectal Prostate Biopsy.
5.
As pesticides and wildfires rise, kids with cancer need resources
1.
Uncovering the Hidden Symptoms of Parathyroid Cancer in Women
2.
Understanding Mesenteric Masses: Symptoms, Diagnosis, and Treatment Options
3.
Multimodal Data Fusion with Deep Neural Networks - Revolutionizing Oncology with Precision Cancer Diagnosis 2025
4.
How is Digital Innovation Revolutionizing Gynecologic Oncology Treatment and Patient Engagement?
5.
The Future of Cancer Care: Genetics, Support Systems, and Emerging Therapies
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part VI
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V
3.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
4.
Navigating the Complexities of Ph Negative ALL - Part IX
5.
Virtual Case Study on Pedal Edema and Triple Vessel Disease - An Initiative by Hidoc Dr.
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation